GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA), and EpiVax Therapeutics Inc, today announced that they have signed an exclusive collaboration agreement to jointly develop and commercialize personalized mRNA-based vaccine candidates for cancers.
Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $7
Keybanc analyst Paul Knight maintains Harvard Bioscience (NASDAQ:HBIO) with a Overweight and lowers the price target from $10 to $7.
